Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17095499 | 0.98 | POLB (0.69) | POLBSMN1; SMN2ALDH1A1HRH3KDM4E | |
| SCHEMBL9612032 | 0.84 | POLB (0.69) | POLBSMN1; SMN2ALDH1A1HRH3KDM4E | |
| SCHEMBL10240068 | 0.84 | ALDH1A1 (0.63) | POLBSMN1; SMN2ALDH1A1HRH3KDM4E | |
| SCHEMBL30596563 | 0.84 | POLB (1.00) | POLBSMN1; SMN2ALDH1A1HRH3KDM4E | |
| SCHEMBL24023500 | 0.84 | POLB (1.00) | POLBSMN1; SMN2ALDH1A1HRH3KDM4E | |
| SCHEMBL24023501 | 0.84 | POLB (1.00) | POLBSMN1; SMN2ALDH1A1HRH3KDM4E | |
| SCHEMBL13293705 | 0.84 | POLB (1.00) | POLBSMN1; SMN2ALDH1A1HRH3KDM4E | |
| SCHEMBL27087826 | 0.83 | HRH3 (0.59) | POLBSMN1; SMN2HRH3SIGMAR1 | |
| SCHEMBL6795896 | 0.82 | POLB (0.96) | POLBSMN1; SMN2ALDH1A1HRH3KDM4E | |
| SCHEMBL28366319 | 0.82 | ALDH1A1 (0.60) | POLBSMN1; SMN2ALDH1A1HRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-01 | — | — | US | disclosed |
| US-20040122026-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20030225288-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003087063-A1 | IMIDAZOLIDINE COMPOUNDS AS CHEMOKINE RECEPTOR MODULATORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | POLB 3185/4885SMN1; SMN2 853/4885ALDH1A1 569/4885 |
| US-20030225288-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | POLB 3185/4885SMN1; SMN2 853/4885ALDH1A1 569/4885 |
| US-20040122026-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | POLB 3185/4885SMN1; SMN2 853/4885ALDH1A1 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.